Skeletal muscle secretome in Duchenne muscular dystrophy: A pivotal anti-inflammatory role of adiponectin
Open accessAbstract
BACKGROUND: Persistent inflammation exacerbates the progression of Duchenne muscular dystrophy (DMD). The hormone, adiponectin (ApN), which is decreased in the metabolic syndrome, exhibits anti-inflammatory properties on skeletal muscle and alleviates the dystrophic phenotype of mdx mice. Here, we investigate whether ApN retains its anti-inflammatory action in myotubes obtained from DMD patients. We unravel the underlying mechanisms by studying the secretome and the early events of ApN. METHODS: Primary cultures of myotubes from DMD and control patients were treated or not by ApN after an inflammatory challenge. Myokines secreted in medium were identified by cytokine antibody-arrays and ELISAs. The early events of ApN signaling were assessed by abrogating selected genes. RESULTS: ApN retained its anti-inflammatory properties in both dystrophic and control myotubes. Profiling of secretory products revealed that ApN downregulated the secretion of two pro-inflammatory factors (TNFα and IL-17A), one soluble receptor (sTNFRII), and one chemokine (CCL28) in DMD myotubes, while upregulating IL-6 that exerts some anti-inflammatory effects. These changes were explained by pretranslational mechanisms. Earlier events of the ApN cascade involved AdipoR1, the main receptor for muscle, and the AMPK-SIRT1-PGC-1α axis leading, besides alteration of the myokine profile, to the upregulation of utrophin A (a dystrophin analog). CONCLUSION: ApN retains its beneficial properties in dystrophic muscles by activating the AdipoR1-AMPK-SIRT1-PGC-1α pathway, thereby inducing a shift in the secretion of downstream myokines toward a less inflammatory profile while upregulating utrophin. ApN, the early events of the cascade and downstream myokines may be therapeutic targets for the management of DMD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ApN disclosed strong anti-inflammatory properties in human myotubes when submitted to an inflammatory challenge.
“Moreover, ApN disclosed strong anti-inflammatory properties in human myotubes when submitted to an inflammatory challenge [56,57].”
From Adiponectin and Its Mimics on Skeletal Muscle: Insulin Sensitizers, Fat Burners, Exercise Mimickers, Muscling Pills … or Everything Together? (2020) · cites this paper as [57]
The anti-inflammatory effects of ApN in human healthy myotubes were linked to activation of the AdipoR1-AMPK-SIRT1-PGC-1α pathway.
“Mechanistically, the anti-inflammatory effects of ApN in human “healthy” myotubes were linked to activation of the AdipoR1-AMPK-SIRT1-PGC-1α pathway [56,57].”
From Adiponectin and Its Mimics on Skeletal Muscle: Insulin Sensitizers, Fat Burners, Exercise Mimickers, Muscling Pills … or Everything Together? (2020) · cites this paper as [57]
Myotubes from DMD patients were unable to produce ApN for local protection, unlike non-dystrophic myotubes challenged by inflammation.
“Moreover, myotubes from DMD patients were unable to produce ApN for local protection [57], unlike non-dystrophic myotubes challenged by inflammation [36].”
From Adiponectin and Its Mimics on Skeletal Muscle: Insulin Sensitizers, Fat Burners, Exercise Mimickers, Muscling Pills … or Everything Together? (2020) · cites this paper as [57]
Secretome analysis from myotubes revealed that ApN down-regulated the secretion of TNFα, IL-17A, sTNFRII, and CCL28.
“secretome analysis from myotubes revealed that ApN down-regulated the secretion of two pro-inflammatory factors (TNFα and IL-17A), one soluble receptor (sTNFRII), and one chemokine (CCL28) [57].”
From Adiponectin and Its Mimics on Skeletal Muscle: Insulin Sensitizers, Fat Burners, Exercise Mimickers, Muscling Pills … or Everything Together? (2020) · cites this paper as [57]
ApN/AdipoRon supplementation induced a shift in the secretion of downstream myokines toward a less inflammatory profile in DMD human myotubes.
“and induced a shift in the secretion of downstream myokines toward a less inflammatory profile.”
From Adiponectin and Its Mimics on Skeletal Muscle: Insulin Sensitizers, Fat Burners, Exercise Mimickers, Muscling Pills … or Everything Together? (2020) · cites this paper as [57]
The mechanisms leading to protective effects of ApN/AdipoRon in DMD involved activation of the AdipoR1-AMPK-SIRT1-PGC-1α axis both in vivo (mdx mice) and in vitro (human dystrophic myotubes).
“As in healthy muscle, the mechanisms leading to the protective effects of ApN/AdipoRon in DMD involved the activation of the AdipoR1-AMPK-SIRT1-PGC-1α axis both in vivo (mdx mice) or in vitro (human dystrophic myotubes) [56,57,103]”
From Adiponectin and Its Mimics on Skeletal Muscle: Insulin Sensitizers, Fat Burners, Exercise Mimickers, Muscling Pills … or Everything Together? (2020) · cites this paper as [57]
ApN/AdipoRon supplementation retained its anti-inflammatory properties in DMD human myotubes.
“We found that ApN/AdipoRon supplementation retained its anti-inflammatory properties in DMD human myotubes [56,57,103]”
From Adiponectin and Its Mimics on Skeletal Muscle: Insulin Sensitizers, Fat Burners, Exercise Mimickers, Muscling Pills … or Everything Together? (2020) · cites this paper as [57]
Silencing each component of the AdipoR1-AMPK-SIRT1-PGC-1α cascade abrogated the effects of ApN/AdipoRon.
“Silencing each component of this cascade abrogated the effects of ApN/AdipoRon.”
From Adiponectin and Its Mimics on Skeletal Muscle: Insulin Sensitizers, Fat Burners, Exercise Mimickers, Muscling Pills … or Everything Together? (2020) · cites this paper as [57]
Up-regulation of utrophin partly substitutes for dystrophin deficiency.
“Third, up-regulation of utrophin partly substitutes for dystrophin deficiency [56,57].”
From Adiponectin and Its Mimics on Skeletal Muscle: Insulin Sensitizers, Fat Burners, Exercise Mimickers, Muscling Pills … or Everything Together? (2020) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · see citing works
Diet-induced insulin resistance in mice lacking adiponectin/ACRP30
Maeda, N., Shimomura, I., Kishida, K., Nishizawa, H., Matsuda, M., Nagaretani, H., Furuyama, N., Kondo, H., Takahashi, M., Arita, Y., et al. (2002) · Nature Medicine · doi:10.1038/nm724 · Cited by 2,086 · see citing works
Yamauchi, T., Nio, Y., Maki, T., Kobayashi, M., Takazawa, T., Iwabu, M., Okada-Iwabu, M., Kawamoto, S., Kubota, N., Kubota, T., et al. (2007) · Nature Medicine · doi:10.1038/nm1557 · Cited by 1,396 · see citing works
Building Muscle: Molecular Regulation of MyogenesisPreprint
Bentzinger, C. F., Wang, Y. X., & Rudnicki, M. A. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008342 · Cited by 1,198 · see citing works
Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome
Maury, E., & Brichard, S. M. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.07.031 · Cited by 1,026 · see citing works
Adiponectin and AdipoR1 Regulate PGC-1α and Mitochondria by Ca2+ and AMPK/SIRT1
Iwabu, M., Yamauchi, T., Okada-Iwabu, M., Sato, K., Nakagawa, T., Funata, M., Yamaguchi, M., Namiki, S., Nakayama, R., Tabata, M., et al. (2010) · Nature · doi:10.1038/nature08991 · Cited by 971 · see citing works
Adiponectin as an anti-inflammatory factor
Ouchi, N., & Walsh, K. X. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.01.026 · Cited by 883 · see citing works
Interleukin-6 Is an Essential Regulator of Satellite Cell-Mediated Skeletal Muscle Hypertrophy
Serrano, A. L., Baeza-Raja, B., Perdiguero, E., Jardí, M., & Muñoz-Cánoves, P. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.011 · Cited by 873 · cited 1× · see citing works
“In line with the anti-inflammatory properties of IL-6, which were also evidenced after muscle exercise [5], this myokine has further been reported to play a beneficial role in muscle regeneration by promoting myoblast differentiation [42].”
BackgroundAdiponectin, the past two decades
Wang, Z. V., & Scherer, P. E. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw011 · Cited by 609 · see citing works
Glucocorticoid corticosteroids for Duchenne muscular dystrophy
Manzur, A. Y., Küntzer, T., Pike, M. G., & Swan, A. V. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub2 · Cited by 539 · see citing works
Corticosteroids for the treatment of Duchenne muscular dystrophy
Matthews, E., Brassington, R., Kuntzer, T., Jichi, F., & Manzur, A. Y. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub4 · Cited by 493 · see citing works
Pathophysiology of Duchenne Muscular Dystrophy: Current Hypotheses
Deconinck, N., & Dan, B. (2006) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2006.09.016 · Cited by 459 · see citing works
Glucocorticoid corticosteroids for Duchenne muscular dystrophy
Manzur, A. Y., Küntzer, T., Pike, M., & Swan, A. V. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub3 · Cited by 434 · see citing works
B cells responses and cytokine production are regulated by their immune microenvironment
Vazquez, M. I., Catalan-Dibene, J., & Zlotnik, A. (2015) · Cytokine · doi:10.1016/j.cyto.2015.02.007 · Cited by 421 · see citing works
Beneficial health effects of exercise – the role of IL-6 as a myokine
Pedersen, B. K., & Fischer, C. P. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.02.002 · Cited by 371 · see citing works
Increased secretion and expression of myostatin in skeletal muscle from extremely obese women
Hittel, D. S., Berggren, J. R., Shearer, J., Boyle, K., & Houmard, J. A. (2009) · Diabetes · doi:10.2337/db08-0943 · Cited by 324 · see citing works
Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis
Diez‐Ruiz, A., Tilz, G. P., Zangerle, R., Baier‐Bitterlich, G., WACHTER, H., & Fuchs, D. (1995) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1995.tb01618.x · Cited by 306 · see citing works
Dynamics of the skeletal muscle secretome during myoblast differentiation
Henningsen, J., Rigbolt, K. T. G., Blagoev, B., Pedersen, B. K., & Kratchmarova, I. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.002113 · Cited by 303 · see citing works
Delaigle, A. M., Jonas, J.-C., Bauche, I. B., Cornu, O., & Brichard, S. M. (2004) · Endocrinology · doi:10.1210/en.2004-0503 · Cited by 241 · see citing works
Anti‐TNFα (Remicade®) therapy protects dystrophic skeletal muscle from necrosis
Grounds, M. D., & Torrisi, J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1024com · Cited by 232 · see citing works
Adipokines oversecreted by omental adipose tissue in human obesity
Maury, E., Ehala-Aleksejev, K., Guiot, Y., Détry, R., Vandenhooft, A., & Brichard, S. M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00127.2007 · Cited by 207 · see citing works
Self-citationRaschke, S., Eckardt, K., Bjørklund Holven, K., Jensen, J., & Eckel, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062008 · Cited by 199 · see citing works
Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells
Shibata, S., Tada, Y., Hau, C. S., Mitsui, A., Kamata, M., Asano, Y., Sugaya, M., Kadono, T., Masamoto, Y., Kurokawa, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms8687 · Cited by 182 · see citing works
Norheim, F., Raastad, T., Thiede, B., Rustan, A. C., Drevon, C. A., & Haugen, F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00326.2011 · Cited by 180 · see citing works
Secretome profiling of primary human skeletal muscle cells
Hartwig, S., Raschke, S., Knebel, B., Scheler, M., Irmler, M., Paßlack, W., Müller, S., Hanisch, F., Franz, T., Li, X., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.08.004 · Cited by 168 · see citing works
Squire, S. E. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.26.3333 · Cited by 167 · see citing works
TNF Receptor 2 and Disease: Autoimmunity and Regenerative Medicine
Faustman, D. L., & Davis, M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00478 · Cited by 160 · see citing works
Le Bihan, M.-C., Bigot, A., Jensen, S. S., Dennis, J. L., Rogowska-Wrzesinska, A., Lainé, J., Gache, V., Furling, D., Jensen, O. N., Voit, T., et al. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.09.008 · Cited by 153 · see citing works
Skeletal muscle as a gene regulatory endocrine organ
Karstoft, K., & Pedersen, B. K. (2016) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000283 · Cited by 132 · see citing works
Paepe, B. D., & Bleecker, J. D. (2013) · Mediators of Inflammation · doi:10.1155/2013/540370 · Cited by 131 · see citing works
The many roles of PGC-1α in muscle — recent developments
Chan, M. C., & Arany, Z. P. (2014) · Metabolism · doi:10.1016/j.metabol.2014.01.006 · Cited by 125 · see citing works
Zanotti, S., Saredi, S., Ruggieri, A., Fabbri, M., Blàsevich, F., Romaggi, S., Morandi, L. O., & Mora, M. (2007) · Matrix Biology · doi:10.1016/j.matbio.2007.06.004 · Cited by 91 · see citing works
Mizuno, Y., Nonaka, I., Hirai, S., & Ozawa, E. (1993) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(93)90190-a · Cited by 87 · see citing works
Cruz‐Guzmán, O. D. R., Rodríguez‐Cruz, M., & Escobar‐Cedillo, R. E. (2015) · BioMed Research International · doi:10.1155/2015/891972 · Cited by 87 · see citing works
Increased levels of interleukin-6 exacerbate the dystrophic phenotype in mdx mice
Pelosi, L., Berardinelli, M. G., Forcina, L., Spelta, E., Rizzuto, E., Nicoletti, C., Camilli, C., Testa, E., Catizone, A., Benedetti, F. D., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv323 · Cited by 71 · see citing works
Globular adiponectin induces differentiation and fusion of skeletal muscle cells
Fiaschi, T., Cirelli, D., Comito, G., Gelmini, S., Ramponi, G., Serio, M., & Chiarugi, P. (2009) · Cell Research · doi:10.1038/cr.2009.39 · Cited by 70 · see citing works
Identification of Differentially Regulated Secretome Components During Skeletal Myogenesis
Chan, C. Y. X., Masui, O., Krakovska, O., Belozerov, V. E., Voisin, S. N., Ghanny, S., Chen, J., Dharsee, M., Zhu, P., Evans, K., et al. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.004804 · Cited by 69 · see citing works
Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives.
Beytia, M., Vry, J., & Kirschner, J. (2012) · PubMed · Cited by 67 · see citing works
Dystrophin deficiency leads to disturbance of LAMP1-vesicle-associated protein secretion
Duguez, S., Duddy, W. J., Johnston, H., Lainé, J., Bihan, M. L., Brown, K. J., Bigot, A., Hathout, Y., Butler-Browne, G. S., & Partridge, T. A. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1248-2 · Cited by 60 · see citing works
Involvement of adiponectin in the pathogenesis of dystrophinopathy
Abou-Samra, M., Lecompte, S., Schakman, O., Noel, L., Many, M. C., Gailly, P., & Brichard, S. M. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0051-9 · Cited by 55 · see citing works
Self-citationAdiponectin and Skeletal Muscle
Jortay, J., Senou, M., Abou-Samra, M., Noel, L., Robert, A., Many, M.-C., & Brichard, S. M. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.03.035 · Cited by 52 · see citing works
Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy
Pasquale, L. D., D’Amico, A., Verardo, M., Petrini, S., Bertini, E., & Benedetti, F. D. (2012) · Neurology · doi:10.1212/wnl.0b013e3182518302 · Cited by 51 · see citing works
Local induction of adiponectin reduces lipopolysaccharide-triggered skeletal muscle damage
Jortay, J., Senou, M., Delaigle, A., Noel, L., Funahashi, T., Maeda, N., Many, M. C., & Brichard, S. M. (2010) · Endocrinology · doi:10.1210/en.2009-1462 · Cited by 44 · see citing works
Self-citationGlobular Adiponectin Activates Motility and Regenerative Traits of Muscle Satellite Cells
Fiaschi, T., Giannoni, E., Taddei, M. L., & Chiarugi, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034782 · Cited by 37 · see citing works
IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse
Kostek, M., Nagaraju, K., Pistilli, E., Sali, A., Lai, S.-H., Gordon, B. S., & Chen, Y.-W. (2012) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-13-106 · Cited by 36 · see citing works
Ge, Q., Rycken, L., Noël, L., Maury, E., & Brichard, S. M. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00153.2011 · Cited by 34 · see citing works
Self-citationA Sensitive Assay of Tumor Necrosis Factor α in Sera from Duchenne Muscular Dystrophy Patients
Saito, K., Kobayashi, D., Komatsu, M., et al. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.10.1703 · Cited by 33 · see citing works
Reeves, E. K. M., Rayavarapu, S., Damsker, J. M., & Nagaraju, K. (2012) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153012799279045 · Cited by 18 · see citing works
IL-6 Blockade as a Therapeutic Approach for Duchenne Muscular Dystrophy
Mammen, A. L., & Sartorelli, V. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.03.018 · Cited by 16 · see citing works
Generation and Use of Cultured Human Primary Myotubes
Cornall, L. M., Hryciw, D. H., Mathai, M. L., & McAinch, A. J. (2012) · InTech eBooks · doi:10.5772/33534 · Cited by 11 · see citing works
Concordant utrophin upregulation in phenotypically discordant DMD/BMD brothers
Vainzof, M., Feitosa, L., Canovas, M., et al. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2016.01.001 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Adiponectin—Consideration for its Role in Skeletal Muscle Health
Krause, M. P., Milne, K. J., & Hawke, T. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071528 · Cited by 121 · see citing works
Abou-Samra, M., Selvais, C. M., Dubuisson, N., & Brichard, S. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072620 · Cited by 72 · see citing works
Self-citationDownregulation of the NLRP3 inflammasome by adiponectin rescues Duchenne muscular dystrophy
Boursereau, R., Abou-Samra, M., Lecompte, S., Noel, L., & Brichard, S. M. (2018) · BMC Biology · doi:10.1186/s12915-018-0501-z · Cited by 72 · see citing works
Self-citation<scp>AdipoRon</scp>, a new therapeutic prospect for Duchenne muscular dystrophy
Abou‐Samra, M., Selvais, C. M., Boursereau, R., Lecompte, S., Noel, L., & Brichard, S. M. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12531 · Cited by 44 · see citing works
Self-citationRole of Adipokines in Sarcopenia
Lu, W., Feng, W., Lai, J., Yuan, D., Xiao, W., & Li, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002255 · Cited by 34 · see citing works
Gamberi, T., Magherini, F., & Fiaschi, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071544 · Cited by 18 · see citing works
- Authors
- Lecompte, S., Abou-Samra, M., Boursereau, R., Noel, L., & Brichard, S. M.
- Affiliations
- UCLouvain (BE)
- Corresponding author
- Brichard, S. M.
- Venue
- Cellular and Molecular Life Sciences
- Published
- 2017-02-10
- Volume
- 74
- Issue
- 13
- Pages
- 2487-2501
- ISSN
- 1420-682X (ISSN-L)
- 1420-9071
- PMC
- PMC5487898
- OpenAlex
- W2586135403
- Cited by
- 34
- References
- 51
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 7 · 2020: 6 · 2019: 2 · 2018: 4 · 2017: 1
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cellular and Molecular Life Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Funders
- Foundation of Scientific and Medical Research (1.5097.12, T.0212.13)
- General Division of Scientific Research (ARC 12 -17/047)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
- Keywords
- Duchenne muscular dystrophy, adiponectin, myokines, muscle inflammation, AdipoR1, TNF-α, IL-17A, CCL28, interleukin-6, myotubes
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Adolescent, Adult, Anti-Inflammatory Agents, Child, Female, Gene Expression Regulation, Humans, Inflammation, Male, RNA, Messenger, Biomarkers, Muscle, Skeletal, Muscle Fibers, Skeletal, Muscular Dystrophy, Duchenne, Proteome, RNA, Small Interfering, Utrophin, Adiponectin, Receptors, Adiponectin, Young Adult, Sirtuin 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
